Company Overview and News


Add BMY
to your dashboard

Headline News

Analysts Expect Eli Lilly to Post Revenue Growth in 3Q17

7h marketrealist
Analysts estimate an increase of ~6.4% in Eli Lilly’s (LLY) 3Q17 revenues to $5.9 billion following the strong performance of some of the company’s existing products as well as new products in 3Q17. (136-0)

What Analysts Project for Eli Lilly in 3Q17

9h marketrealist
Eli Lilly (LLY) is set to release its 3Q17 earnings on October 24, 2017. The company surpassed Wall Street analysts’ estimates for revenues and reported revenues of $5.8 billion for 2Q17 as compared to the estimates of $5.6 billion. The company also surpassed analysts’ EPS estimates and reported EPS of $1.11 per share against the estimates $1.05. (79-0)

Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?

14h zacks
We expect Bristol-Myers Squibb Company (BMY - Free Report) to beat expectations when it reports third-quarter 2017 results on Oct 26, before the market opens. (163-0)

Infinity, Wells Fargo Upgrade, SITC Meeting in November, IPI-549 Update

17h accesswire
NEW YORK, NY / ACCESSWIRE / October 23, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is developing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. (169-2)

Game Plan For The Week - Cramer's Mad Money (10/20/17)

17h seekingalpha
The big earnings week is on the way. Cramer said the earnings better be good so the strength in stocks continue. "I always feel emboldened when we get a real doozy of an earnings report like we did from General Electric (NYSE:GE) and the stock in question comes out the other side unscathed," said Cramer. He will keep an eye on the earnings and the chatter about the tax reform. With that, he discussed his game plan for the week. (396-1)

Heat Biologics and its Pelican Therapeutics Subsidiary Appoint Two New Members to their Scientific Advisory Boards

18h accesswire
DURHAM, NC / ACCESSWIRE / October 23, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), along with its subsidiary, Pelican Therapeutics ("Pelican") have appointed two new members to each of their scientific advisory boards. Joining the boards are Robert B. Levy, Ph.D., Sylvester Comprehensive Cancer Center at the University of Miami, Miller School of Medicine and Professor of Microbiology & Immunology, Ophthalmology and Medicine; and Robert Negrin, M. (86-0)

Celgene, Gilead, Biogen and More Major Biopharmas Reporting This Week

2017-10-22 247wallst
Third-quarter earnings reporting season is now well under way. So far, things are looking good. The health care sector has yet to see any significant earnings representation, but that will change during the week of October 23 to October 27. At least eight large biopharma outfits are scheduled to report their latest earnings and revenues. (362-1)

Roche (RHHBY) Reports Sales Numbers for First 9 Months

2017-10-21 zacks
Roche Holding AG's (RHHBY - Free Report) reported sales of CHF39.4 billion in the first nine months of 2017, up 5% from the year-ago period. (148-0)

Biogen Stock: Performance in 3Q17

2017-10-21 marketrealist
Headquartered in Cambridge, Massachusetts, Biogen (BIIB) is a biopharmaceutical company. It discovers, develops, and manufactures drugs for various therapeutic areas, including immunology, neurology, oncology, and rare diseases. (136-0)

Cancer Treatment Update: Second Gene Therapy Receives Approval

2017-10-21 zacks
With the approval of Gilead Sciences, Inc.’s (GILD - Free Report) Yescarta, this week saw the approval of the second CAR-T therapy for treating cancer. It is regarded as one of the most advanced immune-oncology treatment options. (297-0)

AbbVie Stock: Performance in 3Q17

2017-10-20 marketrealist
Headquartered in Illinois, AbbVie (ABBV) is one of the leading biopharmaceutical companies dealing with research-based pharmaceutical products. It develops and markets pharmaceutical drugs and therapies that address complex and serious diseases worldwide. The company was separated from Abbott Laboratories (ABT) in 2013. (136-0)

Allergan Stock: Performance in 3Q17

2017-10-20 marketrealist
Headquartered in Dublin, Ireland, Allergan (AGN) is one of the leading pharmaceutical companies, dealing with both generic and specialty pharmaceutical products. The US administrative headquarters are in Parsippany, New Jersey. Allergan has segregated its business into three segments: US General Medicine, US Specialized Therapeutics, and the International business. (79-0)

Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?

2017-10-20 zacks
We expect GlaxoSmithKline plc (GSK - Free Report) to beat expectations when it reports third-quarter 2017 results on Oct 25, before the market opens. Last quarter, the company delivered a positive earnings surprise of 2.94%. (139-0)

CELG Stock: Catch This Falling Knife -- Go Long Celgene Corporation | InvestorPlace

2017-10-20 investorplace
Last night, Celgene Corporation (NASDAQ:CELG) released a headline that they canceled phase three for their potential solution to Crohn’s disease. The stock is now trading down 10%. This means that it would now be down 16% since early October. (351-2)

Roche Earnings: In A Competitive Storm With Shaky Defenses - Bloomberg

2017-10-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (122-0)

Market Is Not Waiting For Tax Reform - Cramer's Mad Money (10/18/17)

2017-10-19 seekingalpha
US Treasury Secretary Steven Mnuchin said that the tax reform is baked into the market and if it doesn't go through, it will impact stocks negatively. Cramer thinks otherwise. "Look, I appreciate he's trying to get Congress motivated, but just on the facts, I think he's quite wrong. The truth is, most executives don't believe tax reform is coming. It's simply not integral to this market. Yes, they've lost faith," he said. (156-1)

Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?

2017-10-18 zacks
We expect Biogen Inc. (BIIB - Free Report) , a well-known name in the multiple sclerosis (MS) market, to beat expectations when it reports third-quarter 2017 results on Oct 24, before the market opens. Last quarter, the company delivered a positive earnings surprise of 15.60%. (130-0)

Exploring AstraZeneca's Two-Prong Assault On Lung Cancer

2017-10-18 seekingalpha
AstraZeneca has made huge moves in the 2nd half of 2017, particularly with respect to lung cancer therapy (145-0)

3 Things In Biotech You Should Learn Today: October 18, 2017

2017-10-18 seekingalpha
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. (104-0)

Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?

2017-10-18 zacks
Eli Lilly and Company (LLY - Free Report) will report third-quarter 2017 results on Oct 24, before the market opens. Last quarter, the company delivered a positive earnings surprise of 6.73%. (89-0)

Corporate News Blog - Inovio Initiates Phase-1b/2 Cancer Efficacy Trial

2017-10-18 accesswire
LONDON, UK / ACCESSWIRE / October 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Inovio Pharmaceuticals, Inc. (NASDAQ: INO), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=INO. The Plymouth Meeting , Pennsylvania based clinical-stage pharmaceutical Company announced on October 16, 2017, that it has commenced a phase-1b/2 immuno-oncology trial to evaluate Genentech/Roche's atezolizumab (TECENTRIQ®) in combination with Inovio's INO-5401and INO-9012 for the treatment of advanced bladder cancer. (92-0)

US Pharma Mergers and Acquisitions in 3Q17

2017-10-18 marketrealist
The US pharmaceutical sector consists of different setups pertaining to development, manufacturing or production, and drug marketing. These setups consist of drug manufacturers, drug marketers, and biotechnology companies. (79-0)

Missouri appeals court tosses $72M US award in talcum powder case

2017-10-18 cbc.ca
A Missouri appeals court on Tuesday that vacated a $72 million US award to an Alabama woman who claimed her use of Johnson & Johnson products that contained talcum contributed to her ovarian cancer has thrown the fate of awards in similar cases into doubt. (72-0)

Alexandria Real Estate Equities: Buy Below $110 Per Share

2017-10-17 seekingalpha
Major patent cliffs from 2012-2016 depressed revenues of key tenants. This trend will moderate in the coming years. (113-0)

Appeals court throws out $72-million award in talc powder case due to jurisdictional issue

2017-10-17 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com (72-0)

CUSIP: 011012210